
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Keywords: آزمایشهای تصادفی کنترل شده; Chronic myeloid leukemia; Imatinib; Dasatinib; Nilotinib; Phase 2 clinical trials; Randomized controlled trials